Prescribing overview
Neurontin is human-labeled for postherpetic neuralgia and adjunctive partial-onset seizure treatment. Animal use requires a veterinary plan; renal clearance, sedation and formulation excipients are important reconciliation issues.
Key prescribing checks
- The label emphasizes renal adjustment, somnolence and impaired coordination. Review kidney function and additive sedation with other medicines.
- Respiratory depression is a label concern with CNS depressants or underlying respiratory impairment; excessive sedation or breathing changes need immediate assessment.
- Sudden withdrawal can increase seizure risk. A veterinarian should direct changes to an established anticonvulsant plan rather than staff independently stopping the medication.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Humans (reference label)
Human-approved; veterinary regimen not verifiedPostherpetic neuralgia and adjunctive partial-onset seizure treatment
Neurontin is not pregabalin.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Binds calcium-channel α2δ subunits in vitro; precise therapeutic mechanisms remain uncertain. It does not act by GABA binding.
Absorption, distribution, metabolism and elimination
Humans: eliminated unchanged in urine, without appreciable metabolism; half-life 5–7 hours, prolonged by reduced renal function.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Neurontin
U.S. human capsules, tablets and oral-solution label; not veterinary approval.
Contraindications · when not to use
- Hypersensitivity to gabapentin or product ingredients.
Precautions & monitoring
- Renal impairment, sedation, respiratory impairment and abrupt withdrawal require review; liquid excipients need separate veterinary assessment.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Human labeling describes somnolence, ataxia, hypersensitivity and respiratory depression with CNS depressants or respiratory impairment.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No approved veterinary dose verified in the reviewed human label.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Neurontin
U.S. human capsules, tablets and oral-solution label; not veterinary approval.
- Opioids/CNS depressants increase sedation and respiratory risk; magnesium/aluminum antacids reduce absorption.
Monitoring
Review renal function, sedation and concurrent opioids/CNS depressants.
Client counseling
Avoid abrupt changes to seizure treatment; obtain prescriber-directed withdrawal instructions.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Verify liquid ingredients: branded Neurontin solution contains xylitol. Do not assume different liquids share its formulation.
Brands, formulations & ingredient identity
Active ingredients
Gabapentin
Neurontin contains gabapentin; it is not a synonym for pregabalin. A similar use or drug class does not establish ingredient equivalence.
The Neurontin oral solution lists xylitol as an inactive ingredient. Xylitol is toxic to dogs: do not select a liquid by generic name alone, and verify excipients before dispensing.
Capsules, tablets and solutions differ in strength and handling. Compounded liquids require their own verified concentration and formulation information.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Neurontin
- Formulation
- Oral capsules, tablets and solution
- Label / product scope
- Human product
Human-labeled product; oral solution contains xylitol and needs special veterinary formulation scrutiny.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →